NCCN Guidelines for Early Detection for Prostate Cancer Version 2.2021
The National Comprehensive Cancer Network (NCCN) clinical practice guideline on early detection of prostate cancer is typically updated annually. During 2021, however, there have been significant changes in this area, including the utilization of multiparametric magnetic resonance imaging (mpMRI), the role of DRE in prostate cancer screening, the definition of certain groups at increased risk of prostate cancer, evaluation of germline mutations, and management of high grade prostatic intraepithelial neoplasia.Source: Doc Wire News
Petrylak Explores the Use of Maintenance Avelumab in Metastatic Bladder Cancer
During a virtual Targeted Oncology Case-Based Roundtable event, Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, Yale School of Medicine, director, Prostate and Genitourinary Medical Oncology, and director, Prostate Cancer Translational Research Group, Yale Cancer Center, discussed the case of a 66-year-old woman with metastatic bladder cancer.Source: Targeted Oncology
Society for Assisted Reproductive Technology Fertility Experts Podcast
An educational project of the Society for Assisted Reproductive Technology, this series is designed to provide up to date information about a variety of topics related to fertility testing and treatment such as IVF. The ”Experts” include accomplished professionals: reproductive endocrinologists, reproductive urologists, genetic counselors and mental health professionals who share their knowledge and advice in an informal interview. Are you ready to take the next step towards building your family?Source: SART Fertility Podcast
Dr. Petrylak on Pivotal PARP Inhibitor Trials in mCRPC With DNA Repair Mutations
Daniel P. Petrylak, MD, discusses the pivotal trials that have led to the regulatory approvals of the PARP inhibitors olaparib and rucaparib in patients with metastatic castration-resistant prostate cancer and DNA repair mutations.Source: OncLive TV
Experts Call for Refined Treatment Paradigm in Urothelial Cancer
Treatments for metastatic urothelial cancer are expanding due to the number of immunotherapies available to patients and physicians, but the paradigm for patient treatment needs to be refined according to Dr. Daniel P. Petrylak.Source: Cure Today
FDA Approves Novel Drug Enfortumab Vedotin for Urothelial Cancer
The US Food and Drug Administration has granted accelerated approval to the novel agent enfortumab vedotin (PADCEV, Astellas) for the treatment of locally advanced or metastatic urothelial cancer that has progressed on chemotherapy and immunotherapy.Source: Medscape
Adam Hittelman, MD, PhD appointed Section Chief of Pediatric Urology and Vice Chair of Urology for Faculty Affairs and Administration
Adam Hittelman, MD, PhD, has been appointed Section Chief of Pediatric Urology for Yale New Haven Children’s Hospital and Yale Urology and as Vice Chair of Urology for Faculty Affairs and Administration.
John Onofrey, PhD joins Yale Urology as Assistant Professor
John Onofrey, PhD has been appointed an Assistant Professor of Urology and of Radiology & Biomedical Imaging, effective July 1, 2019. Dr. Onofrey begins this dual appointment after serving as Postdoctoral Associate and Associate Research Scientist in the Department of Radiology & Biomedical Imaging for the last six years.
Yale Pediatric Urology Ranked 16 in Nation by U.S. News & World Report
In today’s release of the U.S. News and World Report rankings of the 2019 Best Children’s Hospitals rankings, Yale New Haven Children’s Hospital (YNHCH) ranked #16 in the nation for urology services. The ranking reflects Yale Urology’s experience, safety, and advanced patient care for our pediatric patients.